Design Therapeutics (DSGN) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DSGN shares.
View DSGN analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12-month target prices for Design Therapeutics' shares. Their DSGN share price forecasts range from $6.00 to $24.00. On average, they anticipate the company's stock price to reach $17.75 in the next twelve months. This suggests a possible upside of 217.5% from the stock's current price.
View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts.

Design Therapeutics' stock was trading at $10.26 at the beginning of 2023. Since then, DSGN shares have decreased by 45.5% and is now trading at $5.59.
View the best growth stocks for 2023 here.

Design Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 7,480,000 shares, an increase of 35.5% from the April 30th total of 5,520,000 shares. Based on an average daily trading volume, of 391,100 shares, the days-to-cover ratio is presently 19.1 days. Approximately 23.0% of the shares of the stock are short sold.
View Design Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our DSGN earnings forecast.

Design Therapeutics, Inc. (NASDAQ:DSGN) released its quarterly earnings data on Tuesday, March, 14th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.03.

ETFs with the largest weight of Design Therapeutics (NASDAQ:DSGN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Neuroscience and Healthcare ETF (IBRN), Principal Healthcare Innovators ETF (BTEC) and BlackRock Future Health ETF (BMED) and

(DSGN) raised $228 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Design Therapeutics trades on the NASDAQ under the ticker symbol "DSGN."

Design Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (6.26%), BlackRock Inc. (5.69%), FMR LLC (1.71%), Principal Financial Group Inc. (1.29%), State Street Corp (1.27%) and Geode Capital Management LLC (1.13%). Insiders that own company stock include Arsani William, Joao Md Siffert, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu.
View institutional ownership trends.

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DSGN stock can currently be purchased for approximately $5.59.

Design Therapeutics (NASDAQ:DSGN) has a market capitalization of $312.76 million and generates $230,000.00 in revenue each year. The company earns $-63,310,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

Design Therapeutics' mailing address is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. The official website for the company is www.designtx.com. The company can be reached via phone at 858-293-4900 or via email at alicia@thrustsc.com.